Introduction
Tumorigenesis is a multistage process involving deregulation of cell proliferation and/or apoptosis. It may involve the activation of proto-oncogenes and the loss of tumor suppressor genes. The proto-oncogene Bcl-2 is activated by a t(14;18) chromosomal translocation and was originally identi®ed as a common causative factor in lymphomagenesis (Kroemer, 1997) . Bcl-2 expression has been detected in many tumor types, including tumors of the intestine, lung, ovary, breast, prostate, and lymphoid tissues.
The Bcl-2 oncoprotein is a 26 kDa integral membrane protein localized to the membranes of the endoplasmic reticulum, mitochondria, and nuclear envelope (Kroemer, 1997) . It is a member of a family of known cell death regulators, and can function to suppress or delay the induction of apoptosis in a number of systems, including prostate (Beham et al., 1997) , skin (Rodriguez-Villanueva et al., 1998) , lymphoid tissues (Strasser et al., 1994) , and mammary gland (JaÈ ger et al., 1997; Lu et al., 1995) . This dysregulation of apoptosis may lead to pathological disorders involving cell accumulation, including cancer. However, it has also been reported that Bcl-2 can play an antiproliferative role in cultured cells (Borner, 1996; Naumovski and Cleary, 1996; O'Reilly et al., 1996; Pietenpol et al., 1994) . Furthermore, in human breast tumors Bcl-2 expression correlates with a low proliferative index and favorable prognosis (Friedrich et al., 1995; Luna-More et al., 1996; Siziopikou et al., 1996) .
Overexpression of human Bcl-2 in the mouse mammary epithelium (WAP-Bcl-2 mice) blocked apoptosis in involuting mammary glands and accelerated c-myc-induced mammary tumorigenesis, probably by inhibiting c-myc-induced apoptosis (JaÈ ger et al., 1997). Furthermore, Bcl-2 overexpression also inhibits cell death at con¯uence or under serum starvation in nontumorigenic mammary epithelial cell lines infected with recombinant retroviruses containing the Bcl-2 gene (Lu et al., 1995; Merlo et al., 1997) .
DMBA-induced carcinogenesis was inhibited in transgenic mice overexpressing a mammary-targeted mutant p53 protein (Li et al., 1995) . The 172 R-L p53 mutant is found in a small subset of human breast tumors, and is very unusual in that it exhibits many properties characteristic of wild-type p53. These include the ability to induce p21/WAF1/Cip1 and the apoptotic pathway. When this p53 mutant was overexpressed in the mammary glands of transgenic mice, normal lobuloalveolar development was inhibited (Li et al., 1994) . By day 17 of pregnancy, lobuloalveolar structures were completely disorganized, and approximately 20% of cells in the mammary glands expressing the transgene were apoptotic (Li et al., 1995) . Furthermore, when these WAP-p53 172 R-L mice and nontransgenic controls were treated with DMBA and examined for mammary tumor development, the mice overexpressing the p53 transgene exhibited a signi®cant increase in mammary gland apoptosis and a signi®cant decrease in the incidence of DMBA-induced mammary tumors (Li et al., 1995) . These combined results indicate that the p53 172 R-L mutant aects lobuloalveolar development and protects against DMBA-induced tumorigenesis through its ability to induce abnormally high levels of apoptosis in the mammary gland. The interaction between the WAP-Bcl-2 and WAP-p53 172 R-L transgenes was studied with respect to apoptosis in the normal mammary gland in order to con®rm that the Bcl-2 transgene was functional in the FVB genetic background. The WAP-Bcl-2 transgene was able to successfully counteract the apoptosis induced by the WAP-p53 172 R-L transgene.
In order to understand the role of Bcl-2 in DMBAinduced carcinogenesis in the murine mammary gland, female WAP-Bcl-2 transgenic mice and nontransgenic littermates were treated with the carcinogen DMBA to induce mammary tumors. Surprisingly, the WAP-Bcl-2 mice in the latter experiments developed tumors with a signi®cantly longer latency than was seen with their nontransgenic counterparts, suggesting that Bcl-2 is playing a protective role in this system. The combined studies suggest that the WAP-Bcl-2 transgene confers both antiapoptotic and antiproliferative activities dependent upon the cellular and developmental context.
Results
WAP-Bcl-2 mice express the proto-oncogene Bcl-2 at high levels in the mammary gland (JaÈ ger et al., 1997). These mice were originally created in a mixed genetic background. In order to avoid problems of strain variation, they were then bred into the FVB genetic background. Mice used for these experiments were progeny of seven or more generations of backcrossing into FVB, and nontransgenic littermates were used as controls in order to eliminate potential interference caused by residual dierences in genetic background. As dierences in genetic background can also aect transgene expression, expression of human (transgenic) Bcl-2 protein in the mammary glands of the backcrossed mice was examined by Western blot ( Figure  1a ). Human Bcl-2 protein is present in extracts of mammary glands from pregnant bitransgenic WAPBcl-2/WAP-p53 172R-L females (lanes 1 and 2). Similar results were seen with gland extracts from pregnant single transgenic WAP-Bcl-2 females (data not shown). No human Bcl-2 protein is present in extracts made from the gland of a pregnant littermate FVB control female (lane 3).
The WAP-Bcl-2 transgene inhibits apoptosis induced by the p53 172 R-L transgene in the mammary gland High levels of apoptosis rendered the mammary gland refractory to DMBA-induced carcinogenesis in the WAP-p53 172 R-L (FVB background) transgenic mouse model (Li et al., 1994) . The glands of the p53 172 R-L mice also displayed aberrant lobuloalveolar development in this study, resulting in failure to lactate (Li et al., 1994) . It was predicted that the WAP-Bcl-2 transgene, if functional in the FVB background, would be able to counteract the apoptosis induced by the p53 172 R-L transgene, thereby also restoring normal gland morphology. In order to test this hypothesis, the WAPBcl-2 mice were crossed with WAP-p53 172R-L mice, and bitransgenic females were generated and bred in order to observe the eects of transgene coexpression in the normal mammary gland. Expression of p53 172 R-L in mammary glands from bitransgenic mice was con®rmed by both Western blotting and immunohistochemistry on paran-embedded sections (data not shown).
Sections of inguinal mammary glands from pregnant and lactating bitransgenic or control mammary glands were TUNEL stained, and the amount of apoptosis in each section was quantitated as described in the Materials and methods. The bitransgenic mammary glands contained signi®cantly less apoptosis than nontransgenic control mammary glands taken at the same developmental stages (Figure 1b) . In particular, the average apoptotic percentage (0.65%) seen in bitransgenic pregnant mammary glands is dramatically less than the 20% apoptosis reported in p53 172 R-L pregnant mammary gland (Li et al., 1995) . This indicates that the WAP-Bcl-2 transgene signi®cantly counteracts the apoptosis induced by the p53 172 R-L mutant, and con®rms that the WAP-Bcl-2 transgene can also function to decrease apoptosis in the FVB background.
Samples of these pregnant and lactating glands were ®xed for immunohistochemical analysis, and the remainder was whole mounted for morphological analysis. Both the pregnant and lactating glands of the nontransgenic mice demonstrated more lobuloalveolar development and less unoccupied glandular space than their bitransgenic counterparts (data not shown). The Bcl-2 transgene was able to dramatically counteract the massive apoptosis induced by the p53 172 R-L mutant, reducing the level in glands from bitransgenic mice to below that seen in control glands. However, the Bcl-2 transgene was unable to fully restore normal glandular morphology during either pregnancy or lactation. The p53 transgene is expressed at more than 100-fold greater levels than endogenous p53 in the mammary gland (Li et al., 1994) , and overexpression of this mutant protein may exert some developmental eects unrelated to induction of apoptosis.
Expression of the WAP-Bcl-2 transgene in the mammary gland increases the latency of tumors induced by DMBA WAP-Bcl-2 females and nontransgenic littermate females were given isografts of donor pituitaries from syngeneic males at 3 ± 5 weeks of age. This treatment stimulates pregnancy-like proliferation of the mammary gland (Medina, 1974) , thereby inducing the WAP promoter-directed transgene expression. To ensure that the isograft was actually eective in each mouse, samples of normal gland were examined to determine whether or not the presence of the transgene aected the morphology of the gland at gross or microscopic levels. Sections of normal gland from each mouse were stained with hematoxylin and eosin and the remainder of the gland was whole mounted for gross morphological analysis (data not shown). These analyses indicated that all of the glands from both groups of mice were much more proliferative and secretory than normal resting glands, thereby indicating that the donor pituitary glands were functional.
In order to determine the eect of the WAP-Bcl-2 transgene on mammary carcinogenesis, isografted WAP-Bcl-2 and nontransgenic females were treated with the carcinogen DMBA as described in Materials and methods. Treated mice were subsequently palpated weekly for mammary tumors for 52 weeks. Surprisingly, the WAP-Bcl-2 females developed tumors with a longer latency period than did the nontransgenic controls, as shown in Figure 2 . The median tumor latencies for the WAP-Bcl-2 and nontransgenic control mice were 44 weeks and 30 weeks, respectively, indicating that the WAP-Bcl-2 mice developed tumors on average 14 weeks later than the nontransgenic FVB controls. Furthermore, by the end of the experiment (52 weeks after the initial carcinogen administration), only 14 of the 24 WAP-Bcl-2 females (58%) had developed palpable mammary tumors. By comparison, 16 of the 19 nontransgenic females (84%) developed palpable mammary tumors over the same time period. The log rank and Wilcoxon tests were rejected with chi-square values of 5.23 (P50.05) and 5.09 (P50.05) respectively, indicating that the dierence in tumor latency between the two groups was statistically signi®cant. No carcinogen-treated mouse developed more than one tumor. The presence of the WAP-Bcl-2 transgene delayed tumorigenesis in this system.
The mammary tumors arising in the two groups of mice were very similar with respect to histological type and frequency of type. Of the tumors examined as histological sections, the majority were squamous adenocarcinomas (67% in tumors from nontransgenic females and 87% in tumors from WAP-Bcl-2 females). This is the typical tumor phenotype induced by DMBA in hormone-stimulated mice. The remaining tumors were type B adenocarcinomas showing varying degrees of dierentiation. The only unusual aspect of the tumor histology occurred in a subset of the tumors appearing in the WAP-Bcl-2 females, which exhibited extensive intracellular keratinization without progressing completely to squame formation. The speci®c role of Bcl-2 in this incomplete transdierentiation of mammary cells is unknown at this time.
The WAP-Bcl-2 transgene does not appear to aect apoptosis in mammary tumors
Factors involved in suppression of tumorigenesis typically either increase apoptosis or reduce cellular proliferation. The mammary tumors arising in the DMBA-treated WAP-Bcl-2 and nontransgenic mice were excised under anesthesia, and samples were ®xed in 10% NBF for immunohistochemical analysis. Additional samples were frozen in liquid nitrogen for protein analysis. At the same time, a mammary gland containing no visible abnormalities (`normal' gland) was also excised from each mouse. One quarter of this gland was ®xed in 10% NBF as above for immunohistochemical analysis, one quarter was frozen in liquid nitrogen as above, and the remainder was whole-mounted in order to observe gland morphology. Protein extracts were prepared from the frozen quarter of normal gland and the frozen tumor samples and used in Western blots to con®rm that the Bcl-2 transgene was still expressed. The Bcl-2 transgene is still expressed in the mammary tumors from DMBAtreated WAP-Bcl-2 mice (Figure 1a , lanes 5 and 6), while there is no human Bcl-2 expression in a mammary tumor arising in a control FVB littermate (Figure 1a, lane 4 ). An additional higher molecular weight band, which may represent a phosphorylated form of Bcl-2 or some cross-reactive material only found in the tumors, was seen in lanes 5 and 6 of Figure 1a .
Apoptosis in sections of normal gland and tumor from both groups of mice was assessed by TUNEL staining followed by determination of the average percentage of apoptotic cells in each section, as described in Materials and methods. Representative TUNEL-stained sections of normal gland and tumor from WAP-Bcl-2 and control mice are shown in Figure  3 . Figure 3a ,b depict representative sections of normal gland and tumor from a WAP-Bcl-2 female, and Figure 3c ,d sections of normal gland and tumor from a control female. Normal gland samples from WAPBcl-2 and nontransgenic females each contained a certain percentage of apoptotic cells, 0.6+0.06% in the WAP-Bcl-2 glands and 1.1+0.16% in the nontransgenic mammary glands (summarized in Figure 5a ). This dierence is statistically signi®cant (P50.015). By contrast, tumors from both groups contained an approximately equal percentage of apoptotic cells, about 2%. These results suggest that the extent of apoptosis in the normal gland is not necessarily a critical factor in the later development of tumors following carcinogen treatment and that the delay in tumor latency observed in these experiments cannot be explained by changes in apoptosis resulting from expression of the WAP-Bcl-2 transgene.
The WAP-Bcl-2 transgene may aect cellular proliferation in tumors Proliferation in sections of the excised tumors and normal mammary glands was assessed by BrdU staining followed by determination of the average percentage of proliferating cells in each section, as described in Materials and methods. Representative BrdU-stained sections of normal gland and tumor from WAP-Bcl-2 and control mice are shown in Figure 4 . Figure 4a ,b depict representative sections of normal gland and tumor from a WAP-Bcl-2 female, and Figure 4c ,d sections of normal gland and tumor from a control female. The per cent proliferation was similar in the mammary gland samples from nontransgenic mice and WAP-Bcl-2 mice; however, there was a striking dierence in proliferation when tumor sections were compared (summarized in Figure 5b ). The average BrdU labeling index for the WAP-Bcl-2 tumor samples was 3.2+0.79%, as compared to 6.5+0.88% for the nontransgenic tumor samples. This dierence Figure 3 Representative TUNEL-stained normal mammary gland and mammary tumor sections from WAP-Bcl-2 and control FVB females. (a) and (b) depict representative sections of normal gland and tumor from a WAP-Bcl-2 female, and (c) and (d) sections of normal gland and tumor from a control female was statistically signi®cant (P50.001). This dierence in proliferation certainly presents a possible explanation for the latency results discussed above, as dierences in proliferation over an extended period of time may result in dramatic eects on tumor latency.
Discussion
Tumors are the end result of an imbalance between cell proliferation and cell death. Overexpression of Bcl-2 in the mammary gland unexpectedly results in signi®cant suppression of DMBA-induced tumorigenesis. As the tumors arose in the nontransgenic mice with shorter latency following carcinogen treatment, it was assumed that there was either reduced apoptosis or increased proliferation in the mammary glands and/or tumors of the nontransgenic mice relative to that occurring in the WAP-Bcl-2 mice. Consequently, levels of apoptosis and proliferation were assessed in the tumors and in normal glands removed during the tumor excision surgery, in both WAP-Bcl-2 and nontransgenic mice. It had initially been expected that the WAP-Bcl-2 mice might develop tumors with a decreased latency as compared to the nontransgenic controls because of the apoptosis-suppressing functions of the Bcl-2 protein, as was reported previously with the human keratin-1. bcl-2 transgenic mouse model (RodriguezVillanueva et al., 1998).
Although very low levels of apoptosis were observed in the normal mammary glands from either WAP-Bcl-2 or nontransgenic mice, there was a signi®cantly increased percentage of apoptosis in the nontransgenic normal gland as compared to the WAP-Bcl-2 mammary gland, which is consistent with previously published results (JaÈ ger et al., 1997). However, levels of apoptosis in both groups of tumors were essentially equivalent. That more apoptosis was detected in the normal glands of the mice that develop tumors earlier following carcinogen treatment (i.e., the nontransgenic mice) suggests that levels of apoptosis in the normal mammary gland are not the critical determinant of susceptibility to early mammary carcinogenesis induced by DMBA.
The analysis of proliferation in the normal gland and tumors from the two groups of mice provides a potential explanation for the observed tumor latency results, since the WAP-Bcl-2 transgene was found to exert an antiproliferative eect. This unexpected antiproliferative eect has also been described in other systems. Expression of Bcl-2 in several colon, lung, and brain tumor cell lines resulted in growth inhibition, which was surprising because expression of Bcl-2 in other cell lines had previously been shown to stimulate growth under conditions in which control cells would undergo apoptosis (Pietenpol et al., 1994) . Expression of Bcl-2 has also been shown to reduce thymocyte proliferation and delay cell cycle entry of mitogenstimulated B and T lymphocytes, and to delay serum et al., 1996) . It has also been reported that cells overexpressing Bcl-2 accumulate in G0/G1 due to a prolongation of the G1 phase of the cell cycle (Borner, 1996) . A further potential explanation for the eect of Bcl-2 on the cell cycle was proposed by Naumovski and Cleary (1996) , who determined that the p53-binding protein 53BP2 also interacts with Bcl-2, and impedes cell cycle progression at G2/M. It appears that the WAP-Bcl-2 transgene has an antiproliferative eect in the current mammary model system, but the speci®c mechanism by which it exerts this eect is currently unknown.
In the present study, the WAP-Bcl-2 transgene was induced hormonally by the pituitary isograft 2 weeks prior to the ®rst of two carcinogen treatments. Christov et al. (1993) have shown that maximal mammary proliferation (7.7 ± 10.7%) occurs at approximately three weeks post-isograft and decreases back to the baseline after 5 ± 8 weeks. If the Bcl-2 transgene is exerting an antiproliferative eect in the transgenic mammary glands, the maximal dierence in proliferation between that and the nontransgenic gland would theoretically be seen at almost exactly the same time as the carcinogen treatments, which were performed at weeks 2 and 3 post-isograft. The DMBA would be more likely to induce tumors in a more proliferative population (i.e., the nontransgenic mammary glands) which could provide the explanation for the shorter tumor latency in the FVB control mice. The initial observed antiapoptotic eect of the WAP-Bcl-2 transgene in the normal gland is most likely overwhelmed by the subsequent antiproliferative eect, leading to the observed increase in WAP-Bcl-2 mammary tumor latency.
The observed tumor latency and proliferation data are also consistent with previous reports indicating that Bcl-2 expression in invasive human breast cancers is associated with favorable prognostic indicators such as low histologic grade and estrogen and progesterone receptor positivity (Friedrich et al., 1995; Luna-More et al., 1996; Siziopikou et al., 1996) . Estrogen induces expression of Bcl-2 in estrogen-responsive breast cancer cells (Teixeira et al., 1995) , thereby associating Bcl-2 expression with breast cancers that are still hormonedependent. Most strikingly, Bcl-2 expression in human breast cancers is associated with low proliferation rate. This is consistent with the results of the current study, and suggests that the WAP-Bcl-2 mouse model is an appropriate one in which to study the signi®cance of Bcl-2 and its eects on apoptosis and proliferation in human invasive breast cancers.
In previous experiments, Bcl-2 has been shown to accelerate the development of c-myc-induced mammary tumors by reducing c-myc-induced apoptosis, although this study did not address proliferation in normal gland or in tumors (JaÈ ger et al., 1997) . In ®broblasts it is known that c-myc induces apoptosis in a p53-dependent manner (Hermeking and Eick, 1994) . In our study, the WAP-Bcl-2 transgene could partially rescue the nonlactational phenotype of the p53 172 R-L mutant mice in bitransgenic females by counteracting the strongly apoptosis-inducing eects of the latter transgene, which is consistent with these ®ndings (Hermeking and Eick, 1994) . It has been reported that Bcl-2 and p53 serve in a common cell death pathway as repressor and eector, respectively (Marin et al., 1994) . In this lymphoma system, Bcl-2 also suppresses p53-mediated apoptosis (Marin et al., 1994) . At present, it is not known how the p53 transgene might mediate its apoptosis-independent eects on mammary gland morphology. These results demonstrate that this Bcl-2 transgene may also play an important role in the control of normal mammary gland development and tumorigenesis by in¯uencing apoptosis, particularly in the presence of some very strong proapoptotic factor. Therefore, whether the net eect of Bcl-2 expression in the mammary gland is antiproliferative or antiapoptotic may depend on the types of genetic interactions that occur during development and in tumors, and particularly, on the timing of Bcl-2 expression relative to other events occurring in the mammary gland.
This WAP-Bcl-2 transgene has been shown to possess both antiapoptotic and antiproliferative activities. However, the proliferation-suppressing eects of the WAP-Bcl-2 transgene correlate with the clinical picture seen in human tumors overexpressing Bcl-2, suggesting that in both human and mouse breast tumors, Bcl-2-mediated antiproliferative activity is associated with a favorable prognostic correlation.
Materials and methods

Mice
The original WAP-Bcl-2 mice (mixed C57/b16 and DBA/2 background) have been described previously (JaÈ ger et al., 1997), as have the WAP-p53 172 R-L mice (Li et al., 1994) . Nontransgenic FVB mice were acquired from Charles River Labs (Wilmington, MA, USA). Animals were kept in a temperature and light-cycle controlled animal facility. Mice were screened for the presence of the appropriate transgene(s) using PCR-based protocols (JaÈ ger et al., 1997; Li et al., 1994) .
Pituitary isografting and carcinogen treatment
In order to ensure continuous hormonal stimulation, which results in expression of WAP-driven transgenes, all mice to be treated with carcinogen (WAP-Bcl-2 or FVB controls) were ®rst given a pituitary isograft under anesthesia (Medina, 1974) . In this procedure, one donor syngeneic pituitary gland was implanted under the kidney capsule of each (3 ± 5 week old) experimental mouse. Carcinogen treatment was started 2 weeks later, and consisted of two 0.5 mg doses of DMBA (Sigma, St. Louis, MO, USA) administered 7 days apart by gavage.
Isolation of tumors and mammary glands
Tumors and uninvolved (non-tumor-bearing) mammary glands from the same mice were surgically excised under anesthesia from carcinogen-treated WAP-Bcl-2 female mice or nontransgenic FVB female littermates when the tumors reached approximately 161 cm in size. The tumor and normal gland samples were ®xed in 10% neutral buered formalin (NBF) for 6 ± 8 h. The samples were stored in 70% ethanol, and then paran-embedded and sectioned (5 mm sections, Probe-On Plus slides) for immunohistochemical analysis. Whole gland samples were ®xed overnight in 10% NBF and stored in 70% ethanol prior to staining.
Statistical analysis of tumor latency
We estimated median survival times for the WAP-Bcl-2 and nontransgenic FVB control groups and tested for equality in survival distributions using the chi-square distributed (one degree of freedom) nonparametric logrank and Wilcoxon tests.
Western analysis
Extracts of frozen normal gland and tumor samples were prepared as described in JaÈ ger et al. (1997) and electrophoresed on a 12% acrylamide gel. After transfer, the membrane was blocked for 1 h in 5% nonfat dry milk (NFDM), and subsequently incubated in a 1 : 750 dilution of the mouse monoclonal antibody Bcl-2 (100) in 3% NFDM. This antibody speci®cally recognizes human Bcl-2, and was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) After washing, the membrane was then incubated in a 1 : 2000 dilution (3% NFDM) of anti-mouse biotinylated secondary antibody, followed by an incubation in a 1 : 2500 dilution (3% NFDM) of horseradish peroxidase/streptavidin solution, treatment with ECL reagents, and exposure to ®lm.
TdT dUTP nick end labeling (TUNEL) and BrdU analysis TUNEL was performed as described (Gavrieli et al., 1992) with modi®cations as described in Humphreys et al. (1996) . BrdU staining was performed as recommended by the manufacturer's protocol (Amersham Life Sciences, Buckinghamshire, UK). Two hours prior to sacri®ce, all mice were injected with 0.1 ml of BrdU labeling solution (Amersham)/ 10 g body weight, to allow incorporation of BrdU into the DNA of actively replicating cells.
Quanti®cation of apoptosis and cell proliferation
Images from TUNEL-and BrdU-stained tumor sections and normal gland samples from WAP-Bcl-2 mice and FVB controls were captured with a Sony 3CCD color video camera attached to a BX-50 Olympus microscope with Adobe Photoshop software. The number of apoptotic or proliferating cells and the total number of cells in three representative ®elds (1000 ± 1500 cells total per section) were counted, and the percentage of apoptotic or proliferating cells was used in the statistical analysis (by t-test). This was performed using the JMP Statistical Visualization software from SAS Institute, Inc. (Cary, NC, USA). Ten to ®fteen normal mammary glands or tumors from each group (one sample was tested per mouse) were included in the comparisons reported. Clusters of TUNEL-labeled fragments that occurred within the same nuclear diameter were counted as one apoptotic cell.
Note added in proof
Complementary results supporting an anti-proliferative role for Bcl-2 in vivo may be found in the article by Priscilla A Furth et al., (this issue).
